Grant of Options

RNS Number : 5963O

Evgen Pharma PLC

30 January 2019

 

For immediate release                                                                                                                 30 January 2019

Evgen Pharma plc

("Evgen" or the "Company")

Grant of Options

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that, on 28 January 2019, certain employees of the Company including the following Persons Discharging Managerial Responsibility ("PDMR") were granted nil cost options over a total of 826,743 ordinary shares in the Company exercisable, subject to the option vesting, for a period of up to ten years from the date of grant under the Evgen Pharma plc Long Term Incentive Plan ("LTIP").

PDMR	Position	Options granted
Dr Stephen Franklin	Chief Executive Officer	471,061
Richard Moulson	Chief Financial Officer	155,682
Sally Ross	Clinical Development Officer	200,000

The number of nil cost options awarded has been calculated by reference to the three month weighted average share price to 28 January 2018.

These nil cost options are subject to the rules of the LTIP. The options will vest on the third anniversary of grant subject to a minimum absolute total shareholder return (TSR) from the grant date to the vesting date of 10%, at which 25% of the awards will vest, and then on a straight line basis to a 20% TSR at which 100% of the awards will vest. Re-testing of this performance condition after the vesting date is not permitted.

Enquiries:

Evgen Pharma plc Dr Stephen Franklin, CEO Richard Moulson, CFO www.evgen.com	c/o [phone]
finnCap Geoff Nash, Teddy Whiley (Corporate Finance) Alice Lane, Manasa Patil (ECM) www.finncap.com	[phone]
WG Partners LLP Nigel Barnes, Claes Spång	[phone]
Buchanan Mark Court, Sophie Wills, Tilly Abraham [e-mail]	[phone]

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/ 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Steve Franklin
2	Reason for the notification
a)	Position/status	Chief Executive
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Evgen Pharma Plc
b)	Legal Entity Identifier	213800NO3E6TSTQO8K20
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Options over ordinary shares of 0.25 pence each  GB00BSWYN304
b)	Nature of the transaction	Grant of options
c)	Currency	GBP
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		nil	471,061
e)	Aggregated information - Aggregated volume - Price - Aggregated total
f)	Date of the transaction	28 January 2019
g)	Place of the transaction	London Stock Exchange, AIM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Richard Moulson
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Evgen Pharma plc
b)	Legal Entity Identifier	213800NO3E6TSTQO8K20
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Options over ordinary shares of 0.25 pence each  GB00BSWYN304
b)	Nature of the transaction	Grant of options
c)	Currency	GBP
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		nil	155,682
e)	Aggregated information - Aggregated volume - Price - Aggregated total
f)	Date of the transaction	28 January 2019
g)	Place of the transaction	London Stock Exchange, AIM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Sally Ross
2	Reason for the notification
a)	Position/status	Clinical Development Officer
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Evgen Pharma plc
b)	Legal Entity Identifier	213800NO3E6TSTQO8K20
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Options over ordinary shares of 0.25 pence each  GB00BSWYN304
b)	Nature of the transaction	Grant of options
c)	Currency	GBP
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		nil	200,000
e)	Aggregated information - Aggregated volume - Price - Aggregated total
f)	Date of the transaction	28 January 2019
g)	Place of the transaction	London Stock Exchange, AIM

 

END

 

 

DSHSDLFWSFUSEEF